REGENTIS BIOMATERIALS LTD. (RGNT) Form 6-K — Nov 9, 2026
Regentis Biomaterials (NYSE American: RGNT) signed a four-year exclusive distribution agreement with AMI Medical Technologies to commercialize GelrinC® in Israel for knee cartilage repair. AMI is Israel's leading orthopedics distributor with ties to top surgeons, hospitals, and HMOs, and the agreement includes minimum purchase commitments. Regentis expects initial revenue contributions to begin in 2027. GelrinC is already approved in Israel and Europe, and the company's pivotal U.S.
Key figures
- Revenue start
- 2027
- Agreement term years
- 4
- Us phase3 enrollment pct
- over 50% complete
- Annual us cartilage cases
- 470000
- Pain relief duration years
- more than 5
- Procedure duration minutes
- 10
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.